Abstract AB0931 — Table 1. Persistence With Subcutaneously Administered Biologics Among Patients With Psoriatic Arthritis: Analyses From a US CLAIMS DATABASE

K. Oelke1, O. Chambenoit2, A. Majhoo3, S. Gray4, K. Higgins5, P. Hur6
1Rheumatic Disease Center, Glendale, WI; 2Novartis Pharmaceuticals Corporation, East Hanover, NJ; 3Shores Rheumatology, St. Clair Shores, MI; 4Truven Health Analytics, an IBM Company, Cambridge, MA, USA

Background: Persistence with biologic therapies among patients with psoriatic arthritis (PsA) provides insight into the real-world effectiveness of biologics in routine clinical practice. With different dosing schedules and durations of action of currently available biologics, measuring persistence using varying treatment gap cutoffs may better guide physicians in their treatment decisions.

Objectives: To evaluate the persistence of subcutaneously (SC) administered biologics in patients with PsA.

Methods: Patients with ≥1 pharmacy claim for an FDA-approved SC biologic (adalimumab, certolizumab pegol, etanercept, golimumab, and secukinumab) for the treatment of PsA between 01/15/2016 and 07/31/2017 were identified in the Truven Health Analytics MarketScan Commercial and Medicare Supplementary Databases. Eligible patients were aged ≥18 years at the time of biologic initiation (index date) and continuously enrolled with medical and pharmacy claims ≥12 months prior to (baseline period) and ≥12 months after the index date. Patients had ≥1 PsA diagnosis (ICD-9-CM 696.0 or ICD-10-CM L40.5x) and no pharmacy claims for the index biologic during the baseline period. Persistence over 12 months was measured as the discontinuation rate and number of days persistent on the biologic therapy from the index date to reported treatment gaps of ≥45, >90, and >180 days based on clinical expert opinion, or the end of follow-up if no gap was observed. The median time to discontinuation of the index biologic over 12 months was assessed by Kaplan-Meier analysis for each treatment gap cutoff.

Results: A total of 1558 patients with PsA enrolled in the analysis initiated SC biologics, including adalimumab (n=720), certolizumab pegol (n=93), etanercept (n=426), golimumab (n=64), and secukinumab (n=255). Overall, 680 patients (43.6%) discontinued their index biologic therapy during 12 month follow-up. The 12 month discontinuation rate for each treatment gap cutoff was lowest with secukinumab compared with other SC biologics (51.8%, 36.5%, and 21.6% for patients ≥45 days, >90 days, and >180 days, respectively). Mean days persistent on the index biologic was the highest with secukinumab for each treatment gap cutoff (254.5 days, 282.8 days, and 307.5 days for patients with treatment gaps ≥45 days, >90 days, and >180 days, respectively) and etanercept (207.0 days for patients with a treatment gap >180 days; table 1). The median (95% CI) time to discontinuation for patients with a treatment gap >45 days was the highest with secukinumab (308 [238 to >365] days) and lowest with certolizumab pegol (216 [155 to 274] days). Median time to discontinuation could not be calculated for patients with treatment gaps >90 days or >180 days due to low event rates and limited follow-up.

Conclusions: Although overall reactivity to Hp in PsA and Ps is lower than HCs, Hp infection cannot safely be considered a protecting microbial agent for these diseases, as reactivities to some Hp antigens are more frequently recognised to these diseases than HCs.


Abstract AB0932 — Table 1. Survival at 6 and 12 Months of Ustekinumab in Patients with Psoriatic Arthritis in Conditions of Clinical Practice


Introduction: Psoriatic arthritis (PsA) is a chronic inflammatory disease associated with skin psoriasis. Ustekinumab is a monoclonal antibody which inhibits IL-12/23 and has proven efficacy and safety in the treatment of patients with PsA.

Objectives: To determine the survival rate and the reasons for Ustekinumab discontinuation in a patient cohort with PsA in conditions of clinical practice.

Methods: Descriptive, prospective, longitudinal and open study including 66 patients diagnosed with PsA and treated with Ustekinumab at dosis according to the data sheet (45 mg in the 0, 4 and every 12 weeks), except for 3 patients who were administered a 90 mg dose with the aforementioned regimen. The patients were monitored at 6 and 12 months. The following variables were collected: age, sex, years of evolution, previous treatment with Synthetic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and/or biological DMARD. All the adverse events (AE) which caused the discontinuation of the drug in patients who had received at least one dose of Ustekinumab were also collected. The Kaplan-Meier method was used to analyse the survival rate. The survival rate in naïve patients with biologic DMARD was compared with those who had received at least one biologic DMARD treatment before; and patients treated with Ustekinumab in monotherapy with those who were in a combined therapy with DMARDs. The Log-Rank Test was used for the comparative analysis of both subgroups.

Results: Out of the 66 patients of our cohort, 34 (51.5%) were women, whose mean age was 47.2±11.3 years. 49 presented only peripheral affection (74.2%), mainly in polyarticular form, and 10 had mixed affection. The rest presented axil affaction exclusively. Our patients had been suffering from this disease for